First-in-class antibody set to make gastric cancer breakthrough

6 July 2023
us_fda_big

A new kind of antibody developed by Japan’s Astellas Pharma (TYO: 4503) will be considered for approval in the USA under the Priority Review scheme.

Zolbetuximab is a Claudin 18.2-targeted monoclonal antibody, one of a  range of candidates under development addressing this protein, which Astellas plans to market in gastric cancer.

Chief executive Naoki Okamura said: “If approved, zolbetuximab would be the first CLDN18.2-targeted therapy available in the USA for these patients.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology